Abstract
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a patient receiving sorafenib.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Brachytherapy
-
Carcinoma, Renal Cell / drug therapy
-
Carcinoma, Renal Cell / radiotherapy
-
Carcinoma, Renal Cell / secondary
-
Carcinoma, Renal Cell / surgery
-
Drug Eruptions / etiology*
-
Fatal Outcome
-
Humans
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / radiotherapy
-
Kidney Neoplasms / surgery
-
Lentigo / chemically induced*
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary
-
Male
-
Middle Aged
-
Nephrectomy
-
Niacinamide / adverse effects
-
Niacinamide / analogs & derivatives*
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / adverse effects*
-
Phenylurea Compounds / therapeutic use
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
-
Sorafenib
Substances
-
Antineoplastic Agents
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Niacinamide
-
Sorafenib